Last reviewed · How we verify

BT-KTM-I — Competitive Intelligence Brief

BT-KTM-I (BT-KTM-I) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE3 inhibitor. Area: Cardiovascular.

phase 3 PDE3 inhibitor PDE3 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

BT-KTM-I (BT-KTM-I) — Chengdu Brilliant Pharmaceutical Co., Ltd.. BT-KTM-I is a small molecule that targets the PDE3 enzyme.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BT-KTM-I TARGET BT-KTM-I Chengdu Brilliant Pharmaceutical Co., Ltd. phase 3 PDE3 inhibitor PDE3
FosD FosD AstraZeneca marketed Phosphodiesterase 3 (PDE3) inhibitor PDE3
Anagrelide retard Anagrelide retard AOP Orphan Pharmaceuticals AG phase 3 Phosphodiesterase 3 inhibitor Phosphodiesterase 3 (PDE3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE3 inhibitor class)

  1. Chengdu Brilliant Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BT-KTM-I — Competitive Intelligence Brief. https://druglandscape.com/ci/bt-ktm-i. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: